| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Over the last 12 months, insiders at BioAtla, Inc. have bought $0 and sold $0 worth of BioAtla, Inc. stock.
On average, over the past 5 years, insiders at BioAtla, Inc. have bought $26.51M and sold $101.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,000 shares for transaction amount of $9,320 was made by MCBRINN SYLVIA (director) on 2023‑12‑26.
| 2023-12-26 | MCBRINN SYLVIA | director | 4,000 0.0082% | $2.33 | $9,320 | -17.93% | ||
| 2023-12-20 | SHORT JAY M PHD | Chief Executive Officer | 50,000 0.1107% | $2.14 | $106,910 | -2.97% | ||
| 2023-12-19 | Vasquez Christian | See Remarks | 7,495 0.0159% | $2.04 | $15,262 | -1.50% | ||
| 2023-12-19 | STEINMAN LAWRENCE | director | 20,000 0.0427% | $2.05 | $41,048 | -1.50% | ||
| 2023-09-08 | MCBRINN SYLVIA | director | 2,000 0.0044% | $2.54 | $5,080 | -20.92% | ||
| 2023-03-29 | SHORT JAY M PHD | Chief Executive Officer | 40,800 0.0845% | $2.47 | $100,862 | +1.59% | ||
| 2023-03-28 | Vasquez Christian | See Remarks | 20,000 0.0429% | $2.40 | $47,970 | +8.51% | ||
| 2023-03-28 | MCBRINN SYLVIA | director | 4,000 0.0084% | $2.35 | $9,400 | +8.51% | ||
| 2022-12-19 | MCBRINN SYLVIA | director | 3,700 0.0097% | $8.33 | $30,813 | -64.41% | ||
| 2022-11-22 | MCBRINN SYLVIA | director | 2,000 0.0048% | $8.27 | $16,540 | -66.02% | ||
| 2022-08-12 | SHORT JAY M PHD | Chief Executive Officer | 26,350 0.0788% | $7.84 | $206,600 | -46.85% | ||
| 2022-06-21 | SHORT JAY M PHD | Chief Executive Officer | 40,308 0.114% | $2.91 | $117,296 | +40.73% | ||
| 2022-06-07 | Vasquez Christian | See Remarks | 10,000 0.0258% | $2.97 | $29,720 | +25.65% | ||
| 2021-12-02 | Sale | SHORT JAY M PHD | Chief Executive Officer | 4,811 0.0135% | $21.76 | $104,666 | -70.68% | |
| 2021-12-02 | Sale | Smith Scott Andrew | President | 2,984 0.0084% | $21.76 | $64,918 | -70.68% | |
| 2021-12-02 | Sale | WALDRON RICHARD A | Chief Financial Officer | 1,434 0.004% | $21.76 | $31,198 | -70.68% | |
| 2021-12-02 | Sale | Sievers Eric | Chief Medical Officer | 820 0.0023% | $21.76 | $17,839 | -70.68% | |
| 2021-12-02 | Sale | Vasquez Christian | See Remarks | 200 0.0006% | $21.76 | $4,351 | -70.68% | |
| 2021-12-01 | Sale | SHORT JAY M PHD | Chief Executive Officer | 24,321 0.0763% | $23.03 | $560,226 | -69.08% | |
| 2021-12-01 | Sale | Smith Scott Andrew | President | 628 0.002% | $23.03 | $14,466 | -69.08% |
| Cormorant Asset Management, LP | 2292060 3.9235% | $897,570.70 | 1 | 0 | +17.46% | |
| SHORT JAY M PHD | Chief Executive Officer | 1439283 2.4638% | $563,623.22 | 4 | 13 | <0.0001% |
| Smith Scott Andrew | President | 345656 0.5917% | $135,358.89 | 0 | 9 | |
| Levy Guy | director | 217358 0.3721% | $85,117.39 | 1 | 2 | +17.46% |
| WALDRON RICHARD A | Chief Financial Officer | 134469 0.2302% | $52,658.06 | 0 | 7 | |
| Vasquez Christian | See Remarks | 115659 0.198% | $45,292.06 | 3 | 7 | +10.89% |
| Sievers Eric | Chief Medical Officer | 91506 0.1566% | $35,833.75 | 0 | 9 | |
| STEINMAN LAWRENCE | director | 38459 0.0658% | $15,060.54 | 1 | 4 | <0.0001% |
| MCBRINN SYLVIA | director | 15125 0.0259% | $5,922.95 | 5 | 0 | <0.0001% |
$17,168,388 | 54 | -43.55% | $24.67M | |
$6,204,522 | 45 | 1.91% | $25.07M | |
$23,895,365 | 34 | -37.28% | $23.36M | |
$1,995,470 | 22 | 14.01% | $20.11M | |
$139,007,129 | 16 | 47.16% | $26.94M | |
$17,594,514 | 16 | -20.37% | $28.75M | |
BioAtla, Inc. (BCAB) | $79,536,861 | 15 | -6.81% | $22.88M |
$11,247,055 | 15 | -26.49% | $20.97M | |
$25,487,383 | 15 | -4.37% | $22.18M | |
$1,199,157 | 14 | 7.52% | $19.82M | |
$156,381,772 | 11 | 64.80% | $22.92M | |
$36,538,405 | 10 | -21.99% | $21.26M | |
$5,574,954 | 8 | -0.97% | $20.61M | |
$1,184,658 | 4 | -22.17% | $23.52M | |
$5,045,759 | 4 | -11.33% | $25.99M | |
$73,632,168 | 3 | -63.24% | $22.31M | |
$245,940 | 2 | 31.12% | $20.35M | |
$30,190 | 1 | -42.39% | $21.93M | |
$500,000 | 1 | -22.94% | $25.58M |
| Increased Positions | 16 | +16% | 781,078 | +3.18% |
| Decreased Positions | 44 | -44% | 12M | -49.44% |
| New Positions | 6 | New | 309,909 | New |
| Sold Out Positions | 27 | Sold Out | 10M | Sold Out |
| Total Postitions | 72 | -28% | 13M | -46.27% |
| Anson Funds Management Lp | $2,567.00 | 7.93% | 4.6M | +5M | New | 2024-12-31 |
| Acorn Capital Advisors, Llc | $2,250.00 | 6.95% | 4.03M | +4M | New | 2024-12-31 |
| Highbridge Capital Management Llc | $1,400.00 | 4.33% | 2.51M | +3M | New | 2024-12-31 |
| Vanguard Group Inc | $1,023.00 | 3.16% | 1.83M | -52,776 | -2.8% | 2024-12-31 |
| Tang Capital Management Llc | $767.00 | 2.37% | 1.37M | +500,000 | +57.2% | 2024-12-31 |
| Morgan Stanley | $616.00 | 1.9% | 1.1M | -753,748 | -40.56% | 2024-12-31 |
| Millennium Management Llc | $611.00 | 1.89% | 1.1M | -2M | -58.8% | 2024-12-31 |
| Renaissance Technologies Llc | $463.00 | 1.43% | 829,596 | +318,196 | +62.22% | 2024-12-31 |
| Boxer Capital, Llc | $383.00 | 1.18% | 686,347 | 0 | 0% | 2024-09-30 |
| Boxer Capital Management, Llc | $383.00 | 1.18% | 686,347 | +686,347 | New | 2024-12-31 |